ADMA Biologics, Inc., a commercial biopharmaceutical company dedicated to specialty plasma-derived biologics, received approval from the U.S. FDA for the company’s expanded manufacturing process, enabling fractionation and purification of a 4,400-liter plasma pool for the manufacture of Intravenous Immune Globulin (IVIG).   The 4,400-liter IVIG plasma pool scale for BIVIGAM will allow ADMA to expand its manufacturing plant’s total processing capacity from 400,000 liters to an anticipated peak ...